Home > Insider Trading > Filing (0001209191-21-043467)

Filing Details

Accession Number:: 0001209191-21-043467
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-28 16:01:51
Reporting Period:: 2021-06-24

Accepted Time:: 2021-06-28 16:01:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1322505	Albireo Pharma Inc.	ALBO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1741553	Jason Duncan	C/O Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston MA 02109	Chief Legal Officer And Gc	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-24	9,137	$24.04	17,117	No	4	M	Direct
Common Stock	Acquisiton	2021-06-24	863	$24.67	17,980	No	4	M	Direct
Common Stock	Disposition	2021-06-24	10,000	$36.38	7,980	No	4	S	Direct
Common Stock	Acquisiton	2021-06-25	6,300	$24.67	14,280	No	4	M	Direct
Common Stock	Disposition	2021-06-25	6,300	$36.22	7,980	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-06-24	9,137	$0.00	9,137	$24.04
Common Stock	Stock Option (right to buy)	Disposition	2021-06-24	863	$0.00	863	$24.67
Common Stock	Stock Option (right to buy)	Disposition	2021-06-25	6,300	$0.00	6,300	$24.67

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,063	2029-01-21	No	4	M	Direct
30,637	2030-01-20	No	4	M	Direct
24,337	2030-01-20	No	4	M	Direct

Footnotes

Shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.01 to $36.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
Represents 292 shares of common stock and 7,688 restricted stock units. Includes 131 shares of common stock acquired under the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") on May 31, 2021.
This option vested as to 25% of the shares on January 22, 2020 with the remainder vesting in equal installments every three months thereafter, beginning on April 22, 2020 and ending on January 22, 2023.
This option vested as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021.